Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381354 | 0.87 | NR3C2 (0.64) | BRD4NR3C2PGRPKMLMNA | |
| SCHEMBL3380541 | 0.82 | NR3C2 (0.51) | BRD4NR3C2PGRPKLR | |
| SCHEMBL3379789 | 0.78 | NR3C2 (0.78) | BRD4NR3C2PGRPKMLMNA | |
| SCHEMBL3295805 | 0.77 | PGR (0.60) | NR3C2PGR | |
| SCHEMBL4847689 | 0.76 | PGR (0.66) | BRD4NR3C2PGRLMNAALDH1A1 | |
| SCHEMBL3380250 | 0.76 | PGR (0.45) | BRD4NR3C2PGRALDH1A1ESR1 | |
| SCHEMBL3382298 | 0.76 | ALDH1A1 (0.53) | NR3C2PGRALDH1A1L3MBTL1MEN1 | |
| SCHEMBL3378883 | 0.75 | KDM4E (0.50) | BRD4LMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3379672 | 0.74 | NR3C2 (0.62) | BRD4NR3C2PGRPKMPKLR | |
| SCHEMBL10532652 | 0.71 | PGR (0.54) | NR3C2PGRTHRBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160304-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1844768-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160304-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | NR3C2, AGTR1, AGTR2 | BRD4 1233/4885NR3C2 1/4885PGR 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.